Published: November 19, 2025
A new clinical trial is set to investigate the potential retinal protective benefits of Finerenone in patients diagnosed with chronic kidney disease (CKD). Sponsored by Alexandria University, this study will examine whether Finerenone, a mineralocorticoid receptor antagonist, can positively impact retinal nerve fiber layer thickness. This trial is still in the “not yet recruiting” stage, raising interest among the medical, clinical, and regulatory communities.
What is the trial about?
The trial, titled “Retinal Protective Effects of Novel Finerenone in Patients with Chronic Kidney Disease,” has been registered on ClinicalTrials.gov. It aims to evaluate how Finerenone may influence retinal nerve fiber layer thickness in individuals diagnosed with chronic kidney disease. As CKD is a chronic condition that can lead to multiple organ complications, including vision-related effects, the investigation seeks to expand treatment possibilities for these patients.
The intervention involves administering Finerenone, a pharmaceutical agent already known for its ability to address conditions such as hyperkalemia in CKD patients. This study focuses on measuring its potential benefits for retinal health, particularly by examining the thickness of the retinal nerve fiber layer, a critical parameter for maintaining ocular function.
The trial is being carried out under the auspices of Alexandria University. As of the publication date, it has not yet begun recruiting participants, signaling an early stage but substantial promise for advancing CKD management.
Potential impacts on patients and care
If the hypothesis holds true that Finerenone positively affects the retina, it could represent an important advance in CKD patient care. The retina’s nerve fiber layer plays a critical role in visual processing, and its deterioration can lead to significant vision issues.
Chronic kidney disease, particularly at advanced stages, has systemic implications, often exacerbating diabetic retinopathy and other ocular complications. Addressing these effects at their root cause could lead to improved patient outcomes and reduced downstream healthcare costs.
The precision and safety of Finerenone’s mechanism of action are likely to be heavily scrutinized during this trial, given the regulatory expectations for evidence when expanding indications for a drug. Additionally, if results are favorable, future applications could inspire a broader conversation around the integration of Finerenone into multidisciplinary treatment protocols for CKD patients.
Frequently Asked Questions
- What is Finerenone?
Finerenone is a mineralocorticoid receptor antagonist designed to treat CKD-related complications, such as cardiovascular issues and hyperkalemia. - Who is conducting this trial?
The sponsor of this trial is Alexandria University. - What is the key condition being studied?
The focus is on chronic kidney disease and its potential effects on retinal nerve fiber layer thickness. - When will the trial begin?
As of this publication, the trial is listed as not yet recruiting. - How can I find the trial details?
View the ClinicalTrials.gov listing here.
Conclusion
This upcoming trial offers a window into innovative ways Finerenone could benefit CKD patients by addressing retinal complications. Regulatory teams and healthcare providers will want to stay tuned for updates on recruitment and findings.
Disclaimer
This information is intended for professionals in the medical, clinical, and regulatory fields. It does not constitute legal or medical advice. Please consult regulatory guidelines or clinical experts for more specific analysis.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07235891?term=medical+device